Research Achievements - Other -

Cutaneous Squamous Cell Carcinoma Producing Granulocyte Colony-stimulating Factor and Parathyroid Hormone-related Protein: A Case Report and Literature Review

Kumagai Takuya, Saito Masaya, Sato Takahiko, Inoue Junichi, Ishikawa Norihisa, Ono Tsuyoshi, Kono Michihiro, Takahashi Naoto

Internal Medicine ( 一般社団法人 日本内科学会 )  advpub ( 0 )   2025

<p>We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP. </p>

DOI PubMed CiNii Research

LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する

長田 直希, 松岡 紗恵, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹

日本血液学会学術集会 ( (一社)日本血液学会 )  86回   O1 - 1   2024.10

SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる

松岡 紗恵, 長田 直希, 池田 翔, 高橋 直人, 安井 寛, 古川 雄祐, 菊池 次郎, 仲宗根 秀樹

日本血液学会学術集会 ( (一社)日本血液学会 )  86回   O1 - 4   2024.10

TFR後の晩期再発は免疫の調節不全を背景にしている

藤岡 優樹, 植木 重治, 高橋 直人

日本血液学会学術集会 ( (一社)日本血液学会 )  86回   O1 - 5   2024.10

7. Progress in the Treatment of CML

Takahashi Naoto

Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine )  113 ( Suppl ) 120a - 120a   2024.02

DOI CiNii Research

Successful cord blood transplantation for refractory gamma-delta hepatosplenic T-cell lymphoma developed during treatment of Crohn's disease

SAITO Akihito, NARA Miho, FUJISHIMA Takashi, KUROKI Wataru, YAMASHITA Takaya, KOBAYASHI Takahiro, IKEDA Sho, KITADATE Akihiro, KAMEOKA Yoshihiro, TAKAHASHI Naoto

Rinsho Ketsueki ( The Japanese Society of Hematology )  65 ( 1 ) 41 - 46   2024

<p>The patient was a 21-year-old man who had been diagnosed with Crohn's disease and received infliximab and azathioprine six years earlier. He was admitted with fever and fatigue. Peripheral blood examination showed LDH 2,473 U/<i>l</i> and thrombocytopenia, and contrast-enhanced computed tomography (CT) showed hepatosplenomegaly. Bone marrow biopsy and liver biopsy showed CD4+CD56+TCR<i>γδ</i>+CD8⁻ atypical cells, leading to a diagnosis of hepatosplenic T-cell lymphoma (HSTCL). The patient was refractory to CHOP and DA-EPOCH, and therefore received cord blood transplantation with myeloablative conditioning. CT showed reduced in hepatosplenomegaly and peripheral blood examination showed LDH 165 U/<i>l</i> and plt 180,000/µ<i>l</i>, so the patient was discharged on day117. HSTCL is a tumor of immature <i>γδ</i>T cells with a V<i>δ</i>1 mutation in the spleen, and immunodeficiency has been implicated in its pathogenesis. Patients with inflammatory bowel disease treated with azathioprine are known to have an increased risk of lymphoproliferative disease. In this case, use of immunosuppressive drugs for Crohn's disease may have caused malignant transformation of <i>γδ</i> cells in the intestinal epithelium. Although the patient was refractory to chemotherapy, he was able to achieve remission with early cord blood transplantation and long-term survival is expected.</p>

DOI PubMed CiNii Research

Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto

Cancer Chemotherapy and Pharmacology ( Springer Nature )    2024

CiNii Research

t(4;14)陽性多発性骨髄腫に対するMMSET阻害剤

松岡 紗恵, 菊池 次郎, 長田 直希, 窪田 浩一, 喜久里 貢, 小山 裕雄, 菊地 正樹, 安井 寛, 池田 翔, 高橋 直人, 梅原 崇史, 仲宗根 秀樹, 古川 雄祐

日本血液学会学術集会 ( (一社)日本血液学会 )  85回   44 - 44   2023.10

Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.

Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi

Cureus   15 ( 7 ) e42215   2023.07

A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.

DOI PubMed

c-FOSはIKZF1転写活性化複合体の重要な構成要素であり、多発性骨髄腫におけるレナリドマイド耐性を誘導する(c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma)

長田 直希, 菊池 次郎, 安井 寛, 池田 翔, 松岡 紗恵, 高橋 直人, 古川 雄祐

International Journal of Myeloma ( (一社)日本骨髄腫学会 )  13 ( 3 ) 136 - 136   2023.05

Refractory esophageal stricture of esophageal mucous membrane pemphigoid after allogeneic hematopoietic stem cell transplantation

FUJITA Nanako, YAMASHITA Takaya, ABE Fumito, NARA Miho, YOSHIOKA Tomoko, KOGA Hiroshi, ISHII Norito, TAKAHASHI Naoto

Rinsho Ketsueki ( The Japanese Society of Hematology )  64 ( 2 ) 107 - 112   2023

<p>Haploidentical allogeneic hematopoietic stem cell transplantation from her brother was performed on a 41-year-old lady with no prior history of pemphigoid to treat recurrent AML. On day 59 following transplantation, she experienced esophageal stenosis. During immunosuppressive therapy for graft vs. host disease, this condition was controlled with periodic esophageal dilatation (GVHD). Her esophageal stricture, which required periodic dilatation, grew worse after she stopped immunosuppressive therapy because of recurrent AML. The esophageal mucosa was easily hemorrhagic and desquamative. Histologic analysis revealed that the squamous cell layers had been divided. Indirect immunofluorescence was negative for IgG and positive for IgA on the epidermal layers, while direct immunofluorescence showed a linear deposition of IgG on the basement membrane zone. It was determined through immunoblotting utilizing recombinant protein of BP180 C-terminal domain that both IgG and IgA antibodies were present, supporting the diagnosis of mucous membrane pemphigoid with anti-BP180. After allogeneic transplantation, basal epidermal cell destruction by GVHD may result in autoimmune blistering disorders, which expose basement membrane proteins and antigen presentation. A similar mechanism could apply to our situation. For rare GVHD cases, a thorough histological diagnosis is required.</p>

DOI CiNii Research

Postmortem diagnosis of intravascular large B-cell lymphoma after atraumatic splenic rupture due to splenic infiltration

KUROKI Wataru, KOBAYASHI Takahiro, UMAKOSHI Michinobu, KITADATE Akihiro, IMAIZUMI Chihiro, SAITO Masaya, KOBAYASHI Isuzu, FUJISHIMA Masumi, FUJISHIMA Naohito, YOSHIOKA Tomoko, GOTO Akiteru, TAKAHASHI Naoto

Rinsho Ketsueki ( The Japanese Society of Hematology )  63 ( 6 ) 523 - 529   2022

<p>Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and ¹⁸F-FDG PET/CT is useful for the early diagnosis of IVLBCL.</p>

DOI PubMed CiNii Research

Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH

FUJISHIMA Takashi, KAWABATA Yoshinari, MICHISHITA Yoshihiro, KITABAYASHI Atushi, TAKAHASHI Naoto

Rinsho Ketsueki ( The Japanese Society of Hematology )  63 ( 10 ) 1386 - 1391   2022

<p>Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B-cell lymphoma that is frequently associated with HIV infection or other immunodeficiencies. We present a case of HIV-negative primary testicular PBL with long-term complete remission (CR) and successful treatment with bortezomib in combination with EPOCH (V-EPOCH). Because of rapidly increasing right testicular swelling, an 86-year-old man without immunodeficiencies was admitted to our hospital. Following that, a right high orchiectomy was performed. Histopathological and immunohistochemical analyses revealed diffuse infiltration of plasmablastic lymphocytes, which were positive for CD38, CD138, CD56, MUM1, lambda, EBER, and MYC respectively, but negative for CD20. The MIB-1 index was 90%. FDG abnormal uptake was discovered on PET/CT at systemic lymph nodes. There was no abnormal cell infiltration in either the bone marrow or cerebral spinal fluid. He was diagnosed with PBL, clinical-stage IIIE-A, IPI high-intermediate risk. He achieved durable CR more than 30 months after the diagnosis after six courses of V-EPOCH, followed by intrathecal prophylaxis (IT) and adjuvant radiation therapy (total 30 Gy). Although PBL shows an aggressive clinical course and poor prognosis, adequate therapeutic approaches for PBL have not been established due to the rarity of this disease. According to our findings, V-EPOCH combined with IT and adjuvant radiotherapy appeared to be feasible and effective as a frontline treatment for elderly patients with primary testicular PBL.</p>

DOI PubMed CiNii Research

再発難治性ホジキンリンパ腫に対する免疫チェックポイント阻害薬治療の後方視的解析(Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26)

前田 峻大, 小宅 達郎, 久保 恒明, 高畑 武功, 玉井 佳子, 亀岡 吉弘, 高橋 直人, 宮入 泰郎, 村井 一範, 下瀬川 健二, 吉田 こず恵, 菅原 健, 猪倉 恭子, 福原 規子, 張替 秀郎, 佐藤 諒, 石澤 賢一, 田嶋 克史, 齊藤 宗一, 深津 真彦, 池添 隆之, 角田 三郎, 神林 裕行, 三田 正行, 森 甚一, 古和田 周吾, 伊藤 薫樹

日本血液学会学術集会 ( (一社)日本血液学会 )  83回   OS2 - 2   2021.09

成人初期前駆T細胞性急性リンパ性白血病の臨床的特徴と予後に関する後方視的研究 THF-24(Clinical features and prognosis of adult early T-cell precursor acute lymphoblastic leukemia: THF-24)

古川 瑛次郎, 大西 康, 遠宮 靖雄, 原崎 頼子, 深津 真彦, 池添 隆之, 亀岡 吉弘, 高橋 直人, 八田 俊介, 勝岡 優奈, 濱田 宏之, 村井 一範, 小宅 達郎, 伊藤 薫樹, 甲斐 龍幸, 助川 真純, 中嶌 真治, 柳谷 稜, 石澤 賢一, 山口 公平, 高橋 太郎, 張替 秀郎

日本血液学会学術集会 ( (一社)日本血液学会 )  83回   OS3 - 5   2021.09

Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis

Kobayashi T.

International Journal of Hematology ( International Journal of Hematology )    2021

Domestic Co-author

DOI

Primary breast diffuse large B-cell lymphoma in an elderly man maintaining long-term complete response

NOGUCHI Shinsuke, SAITOH Hirobumi, SASAKI Hideto, KAMATA Shuichi, ENOMOTO Katsuhiko, TAKAHASHI Naoto

Rinsho Ketsueki ( The Japanese Society of Hematology )  62 ( 5 ) 341 - 345   2021

<p>Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin's lymphoma that mostly affects women. Here, we report a case of primary breast DLBCL that affected an older man without any autoimmune disease or drug-related female hormones. The patient was a 65-year-old man whose chief complaints were gradually-increasing lump in the right chest and swelling of the right axillary lymph nodes. He was diagnosed with malignant lymphoma through a needle biopsy on suspicion of right breast cancer with right axillary lymph node metastasis. Since the histological type could not be confirmed, right breast mass resection was performed. The patient was referred to our department for treatment because of the diagnoses of primary breast DLBCL, germinal center B-cell type (Hans classification), and clinical stage IIA. In addition to the six courses of R-CHOP therapy, intrathecal injections were used in combination to prevent CNS infiltration. He has been in complete remission for 5 years. Although rare, breast lymphoma can also occur in men; therefore, early histological diagnosis and response to CNS recurrence prevention are important.</p>

DOI

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia

Hino M.

International Journal of Hematology ( International Journal of Hematology )  112 ( 1 ) 24 - 32   2020.07  [Refereed]

Domestic Co-author

DOI

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Ko T.K.

Blood ( Blood )  135 ( 26 ) 2337 - 2353   2020.06  [Refereed]

International Co-author

DOI

好酸球増多疾患・好酸球性肺炎 著明な組織内シャルコー・ライデン結晶を認めた好酸球増多症候群患者

福地 峰世, 植木 重治, 山本 洋平, 奈良 美保, 今野 泰典, 面川 歩, 嵯峨 知生, 守時 由起, 大森 泰文, 高橋 直人, 廣川 誠

アレルギー ( (一社)日本アレルギー学会 )  68 ( 4-5 ) 529 - 529   2019.05

Pharmacokinetics of Tacrolimus Coadministered With Letermovir in Allogeneic Hematopoietic Stem Cell Transplantation Patients.

Guo YM, Abumiya M, Yamashita T, Ubukawa K, Takahashi N

Clinical pharmacology in drug development   8 ( 3 ) 411 - 412   2019.04

DOI PubMed

Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.

Ogawa M, Yokoyama K, Hirano M, Jimbo K, Ochi K, Kawamata T, Ohno N, Shimizu E, Yokoyama N, Yamaguchi R, Imoto S, Uchimaru K, Takahashi N, Miyano S, Imai Y, Tojo A

British journal of haematology   183 ( 5 ) 842 - 845   2018.12

DOI PubMed

INCREASED MEAN PLATELET VOLUME (MPV) AS A POTENTIAL PREDICTOR OF THROMBOPOIETIC RECOVERY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHEMOTHERAPY

Yuko Kikuchi, Ayako Naganuma, Kana Haseyama, Kyoko Ono, Takeshi Kobayashi, Noriko Kobayashi, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Hironobu Shimizu, Makoto Hirokawa

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY ( WILEY )  40   68 - 69   2018.09

Summary of the papers read (international conference)  

秋田県内の多施設調査による骨髄異形成症候群に対するアザシチジンの使用状況と安全性/有効性に関する検討(Azacitidine safety and efficacy in Myelodysplastic syndrome: A multicenter survey in Akita)

渡部 敦, 吉岡 智子, 伊藤 史子, 池田 翔, 郭 永梅, 奈良 美保, 藤島 眞澄, 藤島 直仁, 市川 善一, 中山 豊, 川端 良成, 北林 淳, 桑山 明久, 小笠原 仁, 井上 武, 茂木 睦仁, 仁村 隆, 三田 亜紀子, 道下 吉広, 波多野 善明, 伊藤 貢, 黒木 淳, 手島 和明, 大八木 秀明, 久米 正晃, 野口 晋佐, 鵜生川 久美, 亀岡 吉弘, 高橋 直人

臨床血液 ( (一社)日本血液学会-東京事務局 )  59 ( 9 ) 1780 - 1780   2018.09

成人特発性血小板減少症におけるIGHV4-28/IGHJ4再構成由来IgG型B細胞抗原受容体の高発現(Overexpression of the rearranged IGHV4-28//IGHJ4 gene-derived IgG B-cell receptors in adult ITP)

藤島 直仁, 富樫 賢, 長谷川 諒, 渡部 健, 嵯峨 亜希子, 面川 歩, 嵯峨 知生, 植木 重治, 高橋 直人, 北浦 一孝, 鈴木 隆二, 廣川 誠

臨床血液 ( (一社)日本血液学会-東京事務局 )  59 ( 9 ) 1579 - 1579   2018.09

腸炎を契機に発症した横紋筋融解に伴う急性腎障害

齋藤 雅也, 渡邊 春佳, 阿部 史人, 池田 翔, 奈良 瑞穂, 鵜生川 久美, 佐藤 隆太, 奥山 慎, 亀岡 吉弘, 小松田 敦, 高橋 直人

日本腎臓学会誌 ( (一社)日本腎臓学会 )  60 ( 6 ) 902 - 902   2018.08

[Chronic myeloid leukemia: state-of-the-art management].

Takahashi N

[Rinsho ketsueki] The Japanese journal of clinical hematology ( The Japanese Society of Hematology )  59 ( 6 ) 747 - 754   2018.06

<p>Treatment-free remission leading to a sustained deep molecular response (DMR) following the discontinuation of tyrosine kinase inhibitor (TKI) is a therapeutic goal in patients with chronic myeloid leukemia chronic phase (CML-CP). In 2017, discontinuing TKI treatment at the outside of clinical trials was recommended for the first time by National Comprehensive Cancer Network guidelines. The criteria for TKI discontinuation include at least 3 years of TKI therapy, a stable DMR for ≥2 years, and monthly molecular monitoring during the first 6 months following discontinuation of treatment. Moreover, discontinuing TKI treatment at the outset of clinical trials may soon be recommended by the Japanese CML guidelines. Thus, achieving a sustained DMR is the current focus of research in CML-CP patients without a history of TKI resistance.</p>

DOI PubMed

骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性

池田翔, 北舘明宏, 北舘明宏, 阿部史人, 小林敬宏, 高橋直人, 田川博之

International Journal of Myeloma (Web)   8 ( 2 ) 92 - 92   2018.05

J-GLOBAL

治療への基礎的アプローチ 骨髄腫微小環境で発現上昇する解糖系遺伝子群の治療標的としての可能性

池田 翔, 北舘 明宏, 阿部 史人, 小林 敬宏, 高橋 直人, 田川 博之

International Journal of Myeloma ( 日本骨髄腫学会 )  8 ( 2 ) 92 - 92   2018.05

High-Throughput Sequencing of IgG B-Cell Receptors Reveals the Frequent Usage of the Rearranged IGHV4-28//IGHJ4 Gene in Primary Immune Thrombocytopenia in Adults

Naohito Fujishima, Masaru Togashi, Ryo Hasegawa, Ken Watanabe, Akiko Saga, Ayumi Omokawa, Tomoo Saga, Shigeharu Ueki, Naoto Takahashi, Kazutaka Kitaura, Ryuji Suzuki, Makoto Hirokawa

BLOOD ( AMER SOC HEMATOLOGY )  130   2017.12

Summary of the papers read (international conference)  

0

Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-Positive Mature T-Cell Lymphomas

Kitadate Akihiro, Ikeda Sho, Abe Fumito, Takahashi Naoto, Shimizu Norio, Matsue Kosei, Tagawa Hiroyuki

BLOOD   130   2017.12

Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma

Ikeda Sho, Kitadate Akihiro, Abe Fumito, Takahashi Naoto, Tagawa Hiroyuki

BLOOD   130   2017.12

T細胞リンパ腫においてHDAC阻害剤はCCR4発現を減少させモガムリズマブの作用を減弱させる

北舘 明宏, 池田 翔, 阿部 史人, 手島 和暁, 高橋 直人, 末永 孝生, 田川 博之

日本癌学会総会記事 ( 日本癌学会 )  76回   E - 2025   2017.09

低酸素環境における骨髄腫細胞の生存はH3K9脱メチル化酵素KDM3Aに依存する

池田 翔, 北舘 明宏, 阿部 史人, 高橋 直人, 田川 博之

日本癌学会総会記事 ( 日本癌学会 )  76回   J - 3036   2017.09

悪性リンパ腫におけるイノシトールリン脂質プロファイル

阿部 史人, 中西 広樹, 北舘 明宏, 池田 翔, 亀岡 吉弘, 高橋 直人, 佐々木 雄彦, 田川 博之

日本癌学会総会記事 ( 日本癌学会 )  76回   P - 2236   2017.09

早期LCDDに対してVRD療法が奏功した一例

齋藤 綾乃, 池田 翔, 伊藤 香里, 阿部 史人, 奈良 瑞穂, 奥山 慎, 涌井 秀樹, 小松田 敦, 高橋 直人

日本腎臓学会誌 ( (一社)日本腎臓学会 )  59 ( 6 ) 893 - 893   2017.09

The clinical efficacy of tyrosine kinase inhibitors for patients with Ph-positive ALL

  75 ( 3 ) 287 - 293   2017.09

虚血性持続勃起症(Priapism)を契機に発見された急性骨髄性白血病とWaldenstrom's macroglobulinemiaの重複例

永沼綾子, 菊地優子, 長谷山佳菜, 小野杏子, 小林毅, 小林則子, 北舘明宏, 亀岡吉弘, 高橋直人, 廣川誠

日本検査血液学会雑誌   18 ( 学術集会 ) S182 - S182   2017.06

J-GLOBAL

移植非適応未治療多発性骨髄腫患者に対するLd療法およびレナリドミドの至適血漿中濃度の検討

小林 敬宏, 三浦 昌朋, 新岡 丈典, 鐙屋 舞子, 大八木 秀明, 篠原 良徳, 茂木 睦仁, 黒木 淳, 西成 民夫, 川端 良成, 北林 淳, 道下 吉広, 池田 翔, 志田 青慈, 吉岡 智子, 高橋 直人

International Journal of Myeloma ( 日本骨髄腫学会 )  7 ( 1 ) 71 - 71   2017.04

維持透析併用で自家移植を行い透析離脱できた多発性骨髄腫

荒井 岳史, 池田 翔, 新井 郷史, 今泉 ちひろ, 山下 鷹也, 北舘 明宏, 小林 五十鈴, 小林 敬宏, 奈良 美保, 郭 永梅, 鵜生川 久美, 渡部 敦, 藤島 直仁, 藤島 眞澄, 吉岡 智子, 亀岡 吉弘, 田川 博之, 高橋 直人

臨床血液 ( (一社)日本血液学会-東京事務局 )  58 ( 4 ) 401 - 402   2017.04

骨髄腫細胞において低酸素で上昇するコーディング・ノンコーディング遺伝子の網羅的探索とその機能解析

池田翔, 北舘明宏, 阿部史人, 小林敬宏, 高橋直人, 田川博之

International Journal of Myeloma (Web)   7 ( 1 ) 54 - 54   2017.04

J-GLOBAL

Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H, Tohoku Hematology Forum

International Journal of Hematology   105 ( 5 ) 606 - 613   2017.02

DOI

Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.

Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y, Tohoku Hematology Forum

Leuk Lymphoma.   58 ( 6 ) 1509 - 1511   2017.01

DOI

[Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].

Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N

[Rinsho ketsueki] The Japanese journal of clinical hematology ( The Japanese Society of Hematology )  58 ( 11 ) 2227 - 2231   2017

<p>A 79-year-old male patient presented with systemic lymphadenopathy. A lymph node biopsy revealed effacement of the normal nodal architecture with diffuse proliferation of medium-sized atypical lymphoid cells. Southern blot analyses demonstrated rearrangement of the T-cell receptor gene but not the immunoglobulin heavy chain gene. He was diagnosed with CD20-positive peripheral T-cell lymphoma (PTCL), NOS. Although he achieved partial remission after six cycles of R-CHOP, he relapse occurred after 2 months. CD20-negative conversion was confirmed in the lymph node, which was positive for CCR4, and the skin at the time of relapse. The patient received the GDP regimen as salvage therapy with the addition of vorinostat for skin involvement; however, he failed to respond, and the disease systemically progressed. Furthermore, he also exhibited progression in the skin after stopping vorinostat due to hematologic toxicity. A lymph node biopsy at progression revealed CD20 re-expression by immunohistochemistry. At progression, the patient received mogamulizumab but failed to respond, and he died owing to disease progression 8 months after relapse. In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.</p>

DOI PubMed

Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis

FUJISHIMA Masumi, TAKAHASHI Naoto, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro

Rinsho Ketsueki ( The Japanese Society of Hematology )  58 ( 7 ) 743 - 748   2017

<p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>

DOI PubMed

TAFRO Syndrome with Bilateral Adrenal Hemorrhage

Ito F, Kameoka Y, Nara M, Ubukawa K, Fujishima M, Yoshioka T, Fujishima N, Takahashi N

Nihon Naika Gakkai Zasshi.   106 ( 2 ) 288 - 294   2017

TAFRO Syndrome with Bilateral Adrenal Hemorrhage

Ito Fumiko, Kameoka Yoshihiro, Nara Miho, Ubukawa Kumi, Fujishima Masumi, Yoshioka Tomoko, Fujishima Naohito, Takahashi Naoto

Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine )  106 ( 2 ) 288 - 294   2017

DOI